Abstract
Dermatological/medicament compositions containing a combination of hydroquinone, fluocinolone acetonide and tretinoin are useful for treating the signs of photoaging of the skin.
Claims
- A regime or regimen for treating the signs of photoaging of the skin, comprising administering to a subject in need of such treatment, a thus effective amount of a pharmaceutical/dermatological medicament which comprises a combination of fluocinolone acetonide, hydroquinone and tretinoin.
- A regime or regiment for treating cutaneous hyperpigmentation marks induced by exposure to ultraviolet radiation, comprising administering to a subject in need of such treatment, a thus effective amount of a pharmaceutical/dermatological medicament which comprises a combination of fluocinolone acetonide, hydroquinone and tretinoin.
- A regime or regimen as defined by claim 1 for treating the signs of photoaging of the skin selected from the group consisting of actinic keratosis, mottled hyperpigmentation, solar lentigo, flat pigmented seborrhoeic warts, wrinkles and fine lines, solar elastosis, skin roughness, and freckles, comprising administering to a subject in need of such treatment, a thus effective amount of a pharmaceutical/dermatological medicament which comprises a combination of fluocinolone acetonide, hydroquinone and tretinoin.
- The regime or regimen as defined by claim 1, wherein the signs of photoaging of the skin are selected from among actinic keratosis, mottled hyperpigmentation, solar lentigo and flat pigmented seborrhoeic warts.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament being topically applied onto the affected skin area of said subject.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament comprising from 1% to 10% by weight of hydroquinone relative to the total weight thereof.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament comprising from 2% to 7% by weight of hydroquinone relative to the total weight thereof.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament comprising from about 4% by weight of hydroquinone relative to the total weight thereof.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament comprising from 0.025% to 2% by weight of tretinoin relative to the total weight thereof.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament comprising from 0.025% to 1% by weight of tretinoin relative to the total weight thereof.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament comprising from about 0.05% by weight of tretinoin relative to the total weight thereof.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament comprising from 0.005% to 0.1% of fluocinolone acetonide by weight relative to the total weight.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament comprising from 0.005% to 0.05% of fluocinolone acetonide by weight relative to the total weight.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament comprising from about to 0.01% of fluocinolone acetonide by weight relative to the total weight.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament being formulated as a cream.
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament comprising, in weight percentage relative to the total weight: magnesium aluminum silicate3.00%butylated hydroxytoluene0.04%cetyl alcohol4.00%stearic acid3.00%stearyl alcohol4.00%methyl paraben0.18%propyl paraben0.02%Arlacel ® 165 (glyceryl stearate and3.50%glyceryl monostearate PEG-100 stearate]methyl gluceth-105.00%glycerol4.00%tretinoin0.05%fluocinolone acetonide0.01%citric acid0.05%hydroquinone4.00%sodium metabisulfite0.20%purified water68.95%
- The regime or regimen as defined by claim 1, said pharmaceutical/dermatological medicament further comprising a hydroquinone anti-oxidizing amount of sodium metabisulfite.
- A pharmaceutical/dermatological medicament useful for treating the signs of photoaging of the skin, comprising a combination of fluocinolone acetonide, hydroquinone and tretinoin, formulated into a physiologically acceptable medium therefor.
- The pharmaceutical/dermatological medicament as defined by claim 18, formulated for topical application.
- The pharmaceutical/dermatological medicament as defined by claim 19, formulated as a cream.
- The pharmaceutical/dermatological medicament as defined by claim 18, further comprising a hydroquinone anti-oxidizing amount of sodium metabisulfite.
- The pharmaceutical/dermatological medicament as defined by claim 18, comprising from 1% to 10% by weight of hydroquinone.
- The pharmaceutical/dermatological medicament as defined by claim 22, comprising from 0.025% to 2% by weight of tretinoin.
- The pharmaceutical/dermatological medicament as defined by claim 23, comprising from 0.005% to 0.1% by weight of fluocinolone acetonide.
- The pharmaceutical/dermatological medicament as defined by claim 18, comprising in weight percentage relative to the total weight thereof: magnesium aluminum silicate3.00%butylated hydroxytoluene0.04%cetyl alcohol4.00%stearic acid3.00%stearyl alcohol4.00%methyl paraben0.18%propyl paraben0.02%Arlacel ® 165 (glyceryl stearate and3.50%glyceryl monostearate PEG-100 stearate]methyl gluceth-105.00%glycerol4.00%tretinoin0.05%fluocinolone acetonide0.01%citric acid0.05%hydroquinone4.00%sodium metabisulfite0.20%purified water68.95%
Owners (US)
-
Galderma S.a
(Jan 23 2009)
Explore more patents:
Applicants
-
Galderma Sa
Explore more patents:
Inventors
-
Hexsel Doris Maria
Explore more patents:
CPC Classifications
-
A61K8/63
Explore more patents:
-
A61K8/347
Explore more patents:
-
A61K8/671
Explore more patents:
-
A61K31/05
Explore more patents:
-
A61K31/203
Explore more patents:
-
A61K31/57
Explore more patents:
-
A61K31/585
Explore more patents:
-
A61Q19/08
Explore more patents:
-
A61K2300/00
Explore more patents:
US Classifications
-
514/171
Explore more patents:
Download PDF
Document Preview
Document History
- Publication: May 21, 2009
-
Application:
Nov 17, 2008
US 27211008 A
-
Priority:
May 21, 2007
EP 2007054897 W
-
Priority:
May 19, 2006
FR 0604504 A